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Abstract
Background Pancreatic adenosquamous carcinoma has historically been characterized as having a more aggressive clinical
course than ductal adenocarcinoma. The natural history of this disease, however, is essentially unknown.
Methods We evaluated the clinical characteristics of all patients with pancreatic adenosquamous carcinoma recorded in the
California Cancer Registry 2000–2007 and compared them to those of patients with ductal adenocarcinoma.
Results Ninety-five patients with pancreatic adenosquamous carcinoma and 14,746 patients with ductal adenocarcinoma
were identified. Demographics were similar between subtypes (p>0.05). Disease stage at presentation was also similar; over
50% of each diagnostic group presented with metastatic disease (p=0.62). Surgical resection was more common among
patients with locoregional adenosquamous carcinoma than adenocarcinoma (p=0.0004), but rates of adjuvant therapy
administration were similar (p>0.05). The cohorts’ median overall survival durations were similar in a Cox proportional
hazards model (p=0.45); overall survival was also similar when only patients with resected disease were considered (p=
0.65). Early stage, resection and receipt of radiation or chemotherapy were favorable independent prognostic factors among
patients with adenosquamous carcinoma. The median overall survival duration of patients with resected adenosquamous
carcinoma was 12 months (95% CI, 8–52).
Conclusions Adenosquamous carcinoma has a natural history similar to that of ductal adenocarcinoma when treated with
prevalent clinical patterns of care.
Keywords Pancreatic cancer.Adenosquamous cancer.
Pancreaticoduodenectomy.Adenocarcinoma.Pancreas
Introduction
Adenosquamous carcinoma (ASC) is a rare pancreatic cancer
that is has been suggested to be distinct from pancreatic ductal
adenocarcinoma (AC) both histopathologically and clinically.
1,
2 Histologically, ASC is distinguished from AC by the
presence of both adenocarcinomatous and squamous compo-
nents.
3 Clinically, the disease has been characterized by an
extremely poor prognosis, even relative to that of AC—which
itself is associated with median overall survival durations as
lowas3–6monthsamongpatientswithmetastaticdiseaseand
ashighas24monthsamongpatientswithresectablecancers.
4,
5 Indeed, the median overall survival duration of patients
with localized ASC has been reported to be as low as
6 months following radical tumor resection, with 2-year
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DOI 10.1007/s11605-010-1378-5survival an infrequent event. Patients with advanced ASC
treated with palliative intent have fared even worse.
5–7
The histopathologic phenotype of ASC is well defined and
thus ASC remains a unique diagnostic entity. The clinical
significance of this diagnosis is unclear, however, because its
natural history is poorly understood. Indeed, the demograph-
ics, treatment patterns, and oncologic outcomes of patients
with ASC are essentially unknown because all clinical
knowledge of the disease has been accumulated from case
studies
8–26 and small, single-institution anecdotes—report-
ing patients compiled over a period of decades—the
overwhelming majority of whom had localized disease and
were treated with surgery alone.
2, 5, 7, 27–31 Given the time,
stage, and treatment biases inherent in these previous reports,
we hypothesized that the natural history of ASC has been
mischaracterized and its clinical significance overstated. We
sought to more completely establish the clinical profile of
ASC relative to AC and to elucidate any unique character-
istics that might influence the design of rational treatment
strategies. To these ends, we examined a consecutive series
of patients with ASC recorded in a large state cancer registry
over a recent 8-year time period. We evaluated demographic
and clinical features of ASC, including survival estimates
after treatment with prevalent patterns of care, and compared
these clinical parameters to those of patients with AC treated
in the same recent time period.
Patients and Methods
Cancer Registry
We performed a historical analysis of cases in the
California Cancer Registry database (CCR). The CCR
is the largest contiguous area, population-based cancer
registry in the world, collecting more than 130,000 new
cases yearly. Standardized data collection and quality
control procedures have been in place since 1988.
32, 33
The CCR is part of the National Cancer Institute’s
Surveillance, Epidemiology and End Results (SEER)
Program. Case reporting is estimated at 99% for the state,
and follow-up completion rates exceed 95%.
34, 35 The
CCR has received the highest level of certification from
the North American Association of Central Cancer
Registries.
36 Data were abstracted from medical records
by trained registrars according to standardized proto-
cols.
32, 33 Tumor site and histology were coded according
to standardized criteria.
37
Study Population
Histopathologic diagnoses recorded in the CCR were
ascertained by examination of fine needle aspiration or
surgical specimens by local pathologists. Pancreatic
tumors were identified using the SEER primary site
recode 21100. Pancreatic ductal adenocarcinomas were
identified by ICDO (third edition) histology codes 8140,
8141, 8142, 8144, 8490, 8500, 8501, 8503, 8504,
8507.
37 Adenosquamous carcinomas were identified by
histology code 8560. Other non-ductal cancers were
expressly excluded. All incident cases recorded between
January 2000 and November 2007 for whom complete
follow-up data were available through November 2007
were included for analysis.
Recorded data included demographic information, his-
tology, burden of disease at presentation, first treatment
history, socioeconomic status, and vital status. Socioeco-
nomic status is denoted as a single index variable using
statewide measures of education, income, and occupation
from census data, as described previously.
38, 39 Quintiles
for the socioeconomic status score were used for analysis,
with socioeconomic status 1 and 5 denoting the lowest and
highest quintiles, respectively.
The criteria used for American Joint Commission on
Cancer (AJCC) staging of pancreatic cancer underwent a
dramatic revision between the fifth and sixth editions.
40 In
the CCR, AJCC staging per seventh edition guidelines is
available only for cases diagnosed in or after the year 2004.
We therefore allocated cases by the SEER summary stage
into cohorts with “localized” (no tumor extension or
malignant regional lymphadenopathy regardless of tumor
size), “regional” (based on the presence of either tumor
extension to adjacent viscera or lymph nodes), or “meta-
static” disease. Patients with localized or regional disease in
whom pancreaticoduodenectomy, distal pancreatectomy, or
total pancreatectomy were performed were considered to
have undergone an oncologic resection; patients who
underwent an oncologic resection who received either
chemotherapy or radiation therapy in the first course of
treatment were considered to have undergone adjuvant
therapy. Hospital registrars contacted cases annually, and
CCR staff annually reviewed state death certificates to
identify deceased registry cases.
Statistical Analysis
Clinical characteristics were analyzed with Pearson’s chi-
square test or Fisher’s exact test for categorical and
dichotomous variables and the Student’s t test for compar-
ison of continuous variables. The overall survival duration
(in months) was calculated using dates of diagnosis and
either death from any cause or last contact. The Kaplan–
Meier method was used to generate survival curves. The
log-rank test was used to assess differences between
survival curves. Multivariate survival analyses were per-
formed using Cox proportional hazards ratios. Fifty-five
166 J Gastrointest Surg (2011) 15:165–174Table 1 Demographics and treatment of patients with pancreatic adenosquamous carcinoma and ductal adenocarcinoma reported in California,
2000–2007
Adenosquamous Adenocarcinoma p
N, % 95 (0.39) 14,746 (59.9)
Demographic variables
Age, mean (SD) 68.5 (11.8) 68.6 (11.8) 0.9188
Sex, n (%) 0.1565
Male 55 (57.9) 7,462 (50.6)
Female 40 (42.1) 7,284 (49.4)
Ethnicity, n (%) 0.3740
White 72 (75.8) 9,760 (66.2)
Black 5 (5.3) 1,108 (7.5)
Hispanic 11 (11.6) 2,425 (16.5)
Asian 7 (7.4) 1,365 (9.3)
Other 0 (0) 88 (0.6)
SES quintile, n (%) 0.3013
Lowest 10 (10.5) 2,083 (14.1)
Second lowest 22 (23.2) 2,622 (17.8)
Middle 14 (14.7) 3,153 (21.4)
High 23 (24.2) 3,322 (22.5)
Highest 26 (27.4) 3,566 (24.2)
Clinical stage, n (%)
a 0.6242
Localized 8 (8.9) 976 (7.0)
Regional 34 (37.8) 4,864 (35.1)
Metastatic 48 (53.3) 8,029 (57.9)
Missing data, n (%)
b 5 (5.3) 877 (5.9)
Treatment variables
Any surgery, n (%)
a <0.0001
a
Yes 31 (32.6) 2,428 (16.5)
No 64 (67.4) 12,300 (83.5)
Missing data, n (%)
b 0 (0) 18 (0.1)
Any radiation, n (%)
a 0.1515
a
Yes 20 (21.1) 2,310 (15.7)
No 75 12,422 (84.3)
Missing data, n (%)
b 0 (0) 14 (0.1)
Any chemotherapy, n (%)
a 0.6786
a
Yes 42 (46.2) 6,296 (44.0)
No 49 (53.8) 8,016 (56.0)
Missing data, n (%)
b 4 (4.2) 434 (2.9)
Locoregional patients, n evaluated 42 5,838
Onc. resection, n (%) 0.0004
Yes 26 (61.9) 2,071 (35.6)
No 16 (38.1)
c 3,750 (64.4)
Type of resection, n (%) 0.1084
PD 18 (69.2) 1,690 (81.6)
Distal panc. 5 (19.2) 181 (8.7)
Total panc. 3 (11.5) 200 (9.7)
Tumor diam. (mm); mean (SD)
a 46.3 (19.0) 33.5 (15.1) 0.0001
Missing data, n (%)
b 0 (0) 117 (5.7)
Lymph nodes positive, n (%)
a 0.8562
Yes 15 (57.7) 1,236 (60.2)
J Gastrointest Surg (2011) 15:165–174 167patients (all of whom had AC) in whom a diagnosis of
cancer was made by review of an autopsy report or death
certificate were excluded from all survival analyses. All
analyses were conducted using SAS 9.2 (SAS Institute,
Inc., Cary, NC). Statistical significance was assumed for a
two-tailed p value<0.05.
Results
Demographics of Patients with ASC and AC
Between 2000 and 2007, 24,604 incident cases of
pancreatic neoplasm were recorded in the CCR. Of
these, 14,746 (59.9%) patients with AC and 95 (0.38%)
patients with ASC were included in this analysis.
Demographic data for these patients are reported in
Table 1. The median age at diagnosis, sex, race,
socioeconomic status, and clinical stage of patients with
ASC and AC were similar (p>0.05). The majority of
patients with each diagnosis were Caucasian; sex and
socioeconomic status were evenly distributed. Over 50%
of both groups were found to have metastatic disease upon
presentation. In contrast, localized disease was identified
in less than 10% of incident cases of each histopathologic
subtype.
Treatment Patterns and Pathologic Variables of ASC
and AC
Surgery was utilized more frequently for patients with
ASC than those with AC, both overall (32.6% vs 16.5%,
p<0.0001) and among patients with locoregional cancers
(61.9% vs 35.6%, p=0.0004) (Table 1). Oncologic
procedures performed for patients with ASC included
pancreaticoduodenectomy (n=18), distal (n=5), and total
pancreatectomy (n=3); the distribution of these operations
was similar to that performed for AC (p=0.11). The mean
tumor diameter in resected ASC specimens was larger
than that in AC specimens (46.3 vs 33.5 mm, p=0.0001),
but the frequency of positive lymph nodes was similar
(57.7 vs 60.2%, p=0.86).
Overall, radiation (p=0.15) and chemotherapy (p=0.68)
were administered to similar proportions of patients with
ASC and AC. Twelve (46.2%) patients with ASC who
underwent an oncologic resection were treated with
adjuvant radiation and 13 (52.0%) received chemotherapy.
Rates of administration of adjuvant radiation (p=0.29) and
adjuvant chemotherapy (p=0.99) following resection for
locoregional disease did not differ between groups. Like-
wise, among patients with metastatic disease, the rate of
administration of palliative chemotherapy did not differ
between patients with ASC and AC (p=0.24).
Table 1 (continued)
Adenosquamous Adenocarcinoma p
No 11 (42.3) 816 (39.8)
Missing data, n (%)
b 0 (0) 19 (0.9)
Adj. chemotherapy, n (%)
a 0.9902
Yes 13 (52.0) 1,037 (51.9)
No 12 (48) 962 (48.1)
Missing data, n (%)
b 1 (3.8) 72 (3.5)
Adj. radiation, n (%) 0.2876
Yes 12 (46.2) 747 (36.1)
No 14 (53.8) 1,324 (63.9)
Metastatic patients, n evaluated 46 7,832
Pall. chemotherapy, n (%) 0.2397
Yes 24 (52.2) 3,411 (43.6)
No 22 (47.8) 4,421 (56.4)
The numbers in bold are those which are statistically significant, i.e. p < 0.05
For each variable, data was complete unless otherwise specified
SES socioeconomic status, Onc. oncologic, panc. pancreatectomy, Adj. adjuvant, Pall. palliative, diam. diameter, PD pancreaticoduodenectomy
aPercentage and p values refer to patients with complete data
bPercentage of total patients
cAmong patients with locoregional ASC in whom the reason an oncologic resection was not performed was recorded, surgery was not recommended in 12
(two with localized cancers and ten regional), and one patient refused an operation
168 J Gastrointest Surg (2011) 15:165–174Overall Survival of ASC and AC
Asagroup,themedianoverallsurvivaldurationofallpatients
withASCwas4months(95%CI,3–6)andwassimilartothat
of all patientswith AC(p=0.41,Fig.1a). The median overall
survival duration of patients with ASC was also similar to
that of patients with AC in subpopulations of patients
stratified by age, sex, ethnicity, socioeconomic status,
clinical stage, and the use of oncologic resection, radiation
therapy, and chemotherapy on univariate analysis (p>0.05,
data not shown). Furthermore, the median overall survival
duration of all patients with ASC was similar to that of all
patients with AC in a Cox proportional hazards model after
adjustment for age, gender, ethnicity, socioeconomic status,
stage of disease, and first treatment strategy [hazard ratio
(HR), 1.091; 95% CI, 0.870–1.367; p=0.45] (Table 2).
Finally, when only patients with locoregional cancers who
underwent resection were considered, the median overall
survival duration of patients with each histopathologic
diagnosis were similar after adjustment for age, gender,
ethnicity, socioeconomic status, clinical stage, tumor size,
lymphatic involvement, and the receipt of adjuvant therapy
(HR, 0.886; 95% CI, 0.530–1.482; p=0.65) (Table 3).
Favorable Prognostic Factors among Patients with ASC
Among all patients withASC,favorable prognosticfactors on
univariate analysis included early clinical stage (p<0.0001),
oncologic resection (p<0.0001), receipt of radiation (p<
0.0001), and receipt of chemotherapy (p<0.0233). In a Cox
Fig. 1 a Overall survival of all
patients with pancreatic adenos-
quamous carcinoma and ductal
adenocarcinoma reported in
California, 2000–2007. Dashed
line, adenosquamous carcinoma
(ASC); solid line, pancreatic
ductal adenocarcinoma (AC).
b Overall survival of patients
with localized or regional
adenosquamous carcinoma
stratified by resection status.
Dashed line, resected (R);
solid line, not resected (NR)
J Gastrointest Surg (2011) 15:165–174 169proportional hazards model, each of these factors remained
independently significant (Table 4).
Separate multivariate models were not constructed for
patients with locoregional or metastatic ASC due to
relatively small numbers in each of these subgroups.
Among patients with locoregional ASC, however, those
who underwent an oncologic resection had a median
survival duration of 12 months (95% CI, 8–52) compared
with 5 months (95% CI, 1–12) for those who did not, and
the survival curves were significantly different (p=0.018)
(Fig. 1b). A significant difference in survival could not be
demonstrated between patients with resected locoregional
ASC who did and did not receive adjuvant therapy (p=0.09
overall). Eight patients with locoregional ASC survived
longer than 2 years, four of whom survived over 5 years.
Each of these 5-year survivors underwent surgery and
received adjuvant therapy.
Among patients with metastatic ASC, patients who
receivedchemotherapyhada morefavorablemediansurvival
duration(4.5months;95%CI,3–6months)thanpatientswho
did not (2 months; 95% CI, 1–3 months; p=0.04).
Discussion
ASC and AC share a similar histologic
3 and molecular
41
profile. ASC, however, has long been characterized as
having a natural history distinctly more aggressive than that
of AC. This has led some to question the role of aggressive
treatment strategies for patients with this disease.
2, 5, 7, 27
The clinical significance of this rare diagnosis relative to
AC is unclear, however, because the oncologic behavior of
ASC has been described only by case studies and small,
retrospective surgical series reporting patients with early
Table 3 Cox proportional hazards model for overall survival of
patients with resected locoregional pancreatic adenosquamous carci-
noma and ductal adenocarcinoma reported in California, 2000–2007
HR 95% CI p
Histologic subtype
AC 1.000 (referent)
ASC 0.886 0.530–1.482 0.6454
Age 1.008 1.003–1.014 0.0043
Gender
Male 1.000 (referent)
Female 0.998 0.893–1.116 0.9740
Ethnicity
Caucasian 1.000 (referent)
Black 1.095 0.865–1.387 0.4514
Hispanic 1.043 0.884–1.231 0.6150
Asian 1.007 0.818–1.241 0.9445
Socioeconomic status 0.945 0.905–0.987 0.0112
Clinical stage
Localized 1.000 (referent)
Regional 1.300 1.067–1.583 0.0091
Tumor diameter 1.009 1.005–1.012 <0.0001
Lymphatic involvement
No 1.000 (referent)
Yes 1.386 1.212–1.585 <0.0001
Adjuvant radiation
No 1.000 (referent)
Yes 0.791 0.679–0.922 0.0027
Adjuvant chemotherapy
No 1.000 (referent)
Yes 0.651 0.561–0.756 <0.0001
The numbers in bold are those which are statistically significant, i.e.
p < 0.05
HR hazard ratio for death, 95% CI 95% confidence interval
Table 2 Cox proportional hazards model for overall survival of all
patients with pancreatic adenosquamous carcinoma and ductal
adenocarcinoma reported in California, 2000–2007
HR 95% CI p
Histologic subtype
AC 1.000 (referent)
ASC 1.091 0.870–1.367 0.4509
Age 1.010 1.009–1.012 <0.0001
Gender
Male 1.000 (referent)
Female 0.951 0.918–0.986 0.006
Ethnicity
Caucasian 1.000 (referent)
Black 1.035 0.966–1.108 0.3290
Hispanic 0.955 0.906–1.006 0.0802
Asian 0.922 0.866–0.981 0.0108
Socioeconomic status 0.966 0.953–0.980 <0.0001
Clinical stage
Localized 1.000 (referent)
Regional 1.275 1.177–1.382 <0.0001
Metastatic 2.293 2.117–2.484 <0.0001
Oncologic resection
No 1.000 (referent)
Yes 0.444 0.419–0.472 <0.0001
Any radiation
No 1.000 (referent)
Yes 0.887 0.840–0.936 <0.0001
Any chemotherapy
No 1.000 (referent)
Yes 0.508 0.488–0.528 <0.0001
The numbers in bold are those which are statistically significant, i.e.
p < 0.05
HR hazard ratio for death, 95% CI 95% confidence interval
170 J Gastrointest Surg (2011) 15:165–174stage cancers (Table 5). Moreover, no prior case–control
studies or population-based analyses have been performed to
definitively establish clinical differences between ASC and
AC. In this, the largest study of ASC reported to date, we
used a large cancer registry to evaluate the clinical features
and oncologic outcomes of patients with this diagnosis. Using
a relatively unbiased dataset, we characterize the natural
history of ASC and show that ASC is no more inherently
aggressive than AC. Indeed, we demonstrate that patients
with these two diagnoses have a similar natural history when
treated using prevalent patterns of modern clinical practice.
ASC has been reported to represent up to 4% of
pancreatic neoplasms, but in the largest series of specimens
analyzed at autopsy, ASC was identified in only 0.9%.
42, 43
In this analysis of a large tumor registry, we found a
diagnosis of ASC in approximately 0.4% of 24,604 patients
with newly documented pancreatic malignancies recorded
between 2000 and 2007. This is remarkably similar to the
rate of 0.5% identified in a recent 16-year survey of the
State of Michigan Tumor Registry.
44
Like patients with AC, most of the patients with ASC
presented late in their natural history. Indeed, over 50% of
patients analyzed in this study initially presented with
synchronous distant metastases. Among patients treated
surgically, those with ASC had larger tumors than those with
AC;however,alargerproportionofpatientswithlocoregional
ASC underwent resection than that with AC, and resected
ASC specimens were associated with a similar high rate of
regional lymphatic involvement—approximately 60%—as
AC tumors. Together, these findings reveal that—although
considerably rarer—ASC presents at a similar (albeit ad-
vanced) stage as AC and suggest that the two diagnoses share
a common biologic behavior prior to diagnosis and treatment.
Stage-specific treatment algorithms for patients with AC
are reasonably well-established.
45 In contrast, the absolute
infrequency of ASC has prohibited the development of
standardized treatment protocols for this disease. Indeed,
even the treatment of patients with early stage ASC remains
controversial, due to reportedly dismal survival rates seem-
ingly regardless of intervention.
5, 7 In a recent systematic
review of prior reports, 39 patients with ASC who underwent
surgery for non-metastatic disease had a median survival
duration of 6.8 months (range, 4.6–9) and a 1-year survival
rate of 25.5%.
6 In two recent single-institution series, overall
survival of resected patients was somewhat more favorable.
Among 38 resected patients from Johns Hopkins, the median
overall survival duration was 10.9 months from diagnosis.
27
In another series from the Mayo Clinic, patients who
underwent R0 or R1 resection had a median survival duration
of 14.4 months and 8 months, respectively, compared to
4.8 months among patients treated without an operation.
7
The patients in each group were not described, however,
suggesting that patients who did not undergo resection had
advanced disease, prior comorbidities, a depressed perfor-
mance status, or a combination of these factors.
The efficacy of non-operative therapies among patients
with ASC has not been rigorously evaluated. Only one prior
study has examined the utility of adjuvant chemoradiation for
patientswiththisdisease.Inthatsmall,retrospectiveseries,19
(50%) patients who underwent postoperative chemoradiation
had a more favorable median overall survival than 19 (50%)
patients who did not (13.6 months v. 8.6 months, p=0.005).
27
Although adjuvant chemoradiation was found to be the only
significant prognostic factor with respect to overall survival
on univariate analysis, the analysis suffered from clear
selection bias. No studies have specifically studied the
effects of systemic chemotherapy when administered in the
adjuvant setting, nor its role as palliative therapy for patients
with metastatic disease.
In this study, treatment of patients with ASC by surgical
resection was associated with a more favorable overall
survival relative to no resection, after adjustment for
multiple clinical factors including disease stage. Moreover,
Table 4 Cox proportional hazards model for overall survival of all
patients with pancreatic adenosquamous carcinoma reported in
California, 2000–2007
HR 95% CI p
Age 1.012 0.986–1.038 0.3730
Gender
Male 1.000 (referent)
Female 0.905 0.536–1.528 0.7088
Ethnicity
Caucasian 1.000 (referent)
Black 0.703 0.244–2.023 0.5135
Hispanic 0.890 0.390–2.032 0.7815
Asian 0.655 0.244–1.755 0.3998
Socioeconomic status 0.936 0.765–1.145 0.5915
Clinical stage
Localized 1.000 (referent)
Regional 2.717 0.781–9.451 0.1161
Metastatic 4.690 1.445–15.216 0.0101
Oncologic resection
No 1.000 (referent)
Yes 0.369 0.183–0.747 0.0056
Any radiation
No 1.000 (referent)
Yes 0.474 0.242–0.927 0.0292
Any chemotherapy
No 1.000 (referent)
Yes 0.530 0.300–0.935 0.0285
The numbers in bold are those which are statistically significant, i.e.
p < 0.05
HR hazard ratio for death, 95% CI 95% confidence interval
J Gastrointest Surg (2011) 15:165–174 171the overall survival duration of patients with locoregional
ASC who underwent surgery was similar to that of patients
with locoregional AC who underwent resection in the same
time period. Together with the recent single-institution data
from high-volume pancreatic treatment centers,
7, 27 these
data suggest that resection is a reasonable therapeutic
approach for patients with ASC in whom a margin-
negative resection can be performed safely.
The role of non-operative therapies for patients with
ASC is less clear. Although we could demonstrate no
association between the administration of adjuvant radia-
tion or chemotherapy on the survival of patients with
locoregional ASC following resection, it is interesting that
of the only six 5-year survivors with ASC reported to date
(four in this series and two in the Johns Hopkins series
27),
all received surgery and adjuvant therapy. Among patients
with metastatic ASC, patients who received chemotherapy
had a longer overall survival duration (4.5 vs 2 months)
than patients who did not. The significance of this
finding is uncertain, however, because individual perfor-
mance status—the most influential factor with regard to the
administration of anticancer therapy among patients with
advanced pancreatic malignancy—was not recorded in the
CCR.
46 The absence of recorded performance status represents
a fundamental limitation of this and other analyses of
pancreatic malignancies using large, population-based datasets.
Two other limitations of this study are particularly
noteworthy. Although attempts have been made to identify
characteristic molecular fingerprints that may effectively
distinguish between ASC and AC, the molecular profile of
these two tumors are similar.
41 Therefore, ASC must be
distinguished from AC histopathologically. A strict diagnosis
of ASC requires that a malignant squamous component
represent at least 30% of a routinely sectioned adenocarcino-
ma.
3, 29 This arbitrary cutoff has introduced ambiguity to the
diagnosis of ASC that reflects both the absence of
standardization in histopathologic methods used to process
surgical specimens and the subjectivity with which they are
evaluated. Indeed, when 38 surgical specimens initially
diagnosed as ASC at Johns Hopkins were re-evaluated by
Author (ref.) Number Resected,
n (%)
Median
age (years)
Adjuvant
treatment, n
Median OS
resected, months
Median OS
unresected, months
Skafida
8 1 1 (100) 70 1 CTX 6 NA
Lampropoulos
9 1 1 (100) 72 1 CXRT 24 NA
Voong
27 38 38 (100) 68 19 CTX
19 CXRT
10.9 NA
Kobayashi
10 1 0 (0) 72 NA NA 3
Smoot
7 23 12 (52) 67
a 5 CXRT 13.1 4.8
Hsu
5 12 7 (58) 71 5 CTX 6.51 NR
Jamali
11 1 1 (100) 75 1 CTX 6 NA
Alwaheeb
12 1 1 (100) 45 NR NR NA
Inoue
13 1 0 (0) 61 NA NA 0.83
Murakami
14 2 2 (100) 54 1 CTX
1 CXRT
4.5 NA
Rahemtullah
28 14 2 (14) 70
a NR 13 4
Kardon
29 25 13 (52) 65
a 5 CTX 11.3 3.0
Yamaue
15 1 1 (100) 63 1 CXRT 40 NA
Yavuz
16 2 2 (100) 50 NR 36, NR NA
Komatsuda
17 1 1 (100) 67 0 6 NA
Aranha
18 2 2 (100) 57 2 CXRT 13.5 NA
Madura
2 6 6 (100) 64
a 3 CXRT 5 NA
Nabae
19 2 2 (100) 67 1 RT1 NR 6.5 NA
Lozano
20 3 2 (67) 59
a 3 CXRT
b NR NR
Myung
21 1 1 (100) 64 0 4 NA
Kuji
22 1 1 (100) 73 0 2 NA
Campman
23 1 1 (100) 65 NR NR NA
Onoda
24 1 1 (100) 64 1 CTX 3 NA
Makiyama
25 1 1 (100) 58 0 18 NA
Tanaka
26 1 1 (100) 48 1 CTX 7 NA
Motojima
30 6 3 (50) 67
c NR 7 NR
Yamaguchi
31 8 8 (100) 56
a 0 5.5 NA
Table 5 Published case reports
and clinical series of patients
with pancreatic adenosquamous
carcinoma, 1990–2010
NR not recorded, NA not appli-
cable, CTX chemotherapy,
CXRT chemoradiation,
RT radiation, OS overall survival
aMean
bNeoadjuvant chemoradiation
cResected only
172 J Gastrointest Surg (2011) 15:165–174a single pathologist, 12 (32%) failed to meet strict criteria for
the disease.
27 Significantly, although the presence of any
squamous component was associated with poor prognosis in
the Johns Hopkins study relative to a historic control group of
patients with AC, the proportion of the squamous component
was not associated with overall survival. The rationale for the
strict 30% cutoff is therefore unclear, and several investi-
gators have proposed eliminating this criterion altogether.
29
It is also possible that some diagnoses were coded
incorrectly in the CCR; however, all diagnoses recorded
therein were validated by histopathologic or cytopathologic
analysis. Moreover, accuracy of the histopathologic diag-
noses recorded in large databases has been evaluated and
compared with independent histologic review, with favor-
able results.
47, 48 Nonetheless, the accuracy associated with
the diagnosis of ASC may not be as favorable due to the
stringent diagnostic requirements for this disease. A further
potential for misclassification may exist among patients
with advanced cancer treated non-operatively, for whom a
large surgical specimen for histopathologic evaluation is
absent. The extent to which our conclusions are influenced
by this issue is unknown.
In summary, we conclude that ASC is an extremely rare
subtype of pancreatic cancer that shares many clinical
characteristics—including biologic behavior and overall prog-
nosis—with AC. In this population, the overall survival
duration of all patients with ASC and AC were similar after
adjustment for multiple clinical factors, including stage at
presentation and first treatment strategy. These data therefore
refute prior suggestions that ASC is inherently more aggressive
than AC and imply that a nihilistic view toward patients with
ASC must be avoided. Absent the ability to perform
prospective studies to determine the response of ASC to
individual therapies, and given the molecular, histopathologic
and clinical similarity of these diseases, we recommend the use
of aggressive, stage-specific, multidisciplinary treatment pro-
tocols developed for AC.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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